3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
7
Phase 1/2
4
Phase 3
2
Phase 2
2
Phase NA
1
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Mastocytosis
1
Liver Neoplasms
1
Gastroenteropancreatic Neuroendocrine Tumors
1
GATA2 Deficiency
1
Colorectal Neoplasms
1
Advanced Solid Tumor
1
Interventions
Gemcitabine
5
Capecitabine
4
pembrolizumab
3
Fluorouracil
3
Cisplatin
3
vinflunine
2
enzalutamide
2
cabazitaxel
2
abiraterone
2
Ipilimumab
2
Haloperidol
2
Androgen Antagonists
2
vedolizumab
1
trifluridine tipiracil drug combination
1
relugolix
1
racemetyrosine
1
nimotuzumab
1
nilutamide
1
lanreotide
1
histrelin
1
futibatinib
1
exemestane
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
bicalutamide
1
beta-Glucans
1
auricularum
1
atezolizumab
1
apatinib
1
apalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Neoplasm Metastasis
×
Injections
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled